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Abstract: This study aims to investigate the inhibitory effects of oridonin nanosuspension on 
human prostatic carcinoma PC-3 cell line in vitro. The PC-3 cells were incubated with increasing 
concentrations of oridonin solution and nanosuspensions for 12 hours, 24 hours, and 36 hours. 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was performed to 
measure cellular viability and investigate the effect of oridonin on cell growth of PC-3. Annexin 
V-FITC/PI staining method was used to determine the effect of oridonin by fluorescence micro-
scope and flow cytometry, respectively. Nanosuspension on early apoptosis of PC-3 cells was 
also evaluated. Oridonin significantly inhibited the growth of PC-3 cells after 12 hours, 24 hours, 
and 36 hours of treatment in a dose-dependent manner (P , 0.05). Compared with the same 
concentration of oridonin solution, oridonin nanosuspension enhanced the inhibition ratio of 
proliferation. The observation of propidium iodide fluorescence staining confirmed the MTT 
assay results. The cell proportion of PC-3 at the G2/M phase in the nanosuspension treatment 
group was upregulated compared with that of the control and oridonin solution groups. Both 
oridonin solution and nanosuspension promoted the early apoptosis of PC-3 cells. Furthermore, 
while improving the ratio of early apoptosis, oridonin nanosuspensions also enhanced growth 
suppression, and induced apoptosis of PC-3 cells. This shows great potential in the treatment 
of androgen-independent carcinoma of prostate by oridonin nanosuspensions.
Keywords: oridonin, nanosuspension, carcinoma of prostate, PC-3 cells, cell cycle, 
apoptosis
Introduction
Prostate cancer is the most common malignancy and is the second leading cause of 
  cancer death in men.1,2 Apoptosis is the primary mechanism through which prostate can-
cer cells are killed when exposed to treatments such as chemotherapy or   radiotherapy.3 
Phytochemicals represent a new class of compounds with anticarcinogenic properties 
that are gaining attention in the treatment of human cancers.4 However, many of these 
compounds suffer from sensitivity to degradative processes in the blood, or have limited 
water solubility that provides for minimal dissolution in the gastrointestinal tract and 
low bioavailability.5
Oridonin (ORI) (Figure1), extracted from Rabdosia rubescens, exhibits 
  apoptosis-inducing activities on a variety of cancer cells.6 It has been reported that ORI 
suppresses the growth of MCF-7 cells through the induction of S cell cycle arrest 
and apoptosis and breast cancer cells cultured in vitro but does not affect normal 
human cells.7 Furthermore, it has been demonstrated that ORI effectively inhibits 
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(LNCaP, DU145, PC-3), with ED50s ranging from 1.8 to 
7.5 µg/mL.8 In addition, the literature also describes the 
effects of ORI on cell proliferation, cell apoptosis, cell cycle 
parameters, androgen receptor, and prostate-specific antigen 
protein expression.9 Unfortunately, the poor solubility of 
ORI in water and physiologically acceptable organic solvent 
imposes some restraints to further pharmaceutical use.10 
ORI is a poorly soluble drug; for example, the solubility in 
water is ,1 mg/mL.11 The poor solubility may be overcome 
by particle size reduction using nanoscience approach.12 
A nanoscience approach that has quickly gained a proven 
record within the pharmaceutical sciences is the formulation 
as nanosuspension.13 Nanosuspensions of drugs are submi-
cron colloidal dispersions of pure particles of drug which 
are stabilized by surfactants.14 Currently, various delivery 
platforms have been explored to improve bioavailability by 
increasing dissolution rate and solubility.15 Nevertheless, 
several conventional approaches have encountered many 
limitations with regards to their application, such as increased 
toxicity. These conventional approaches often attempt to 
solubilize insoluble drugs with the use of excessive amounts 
of cosolvents, but this poses toxicity problems. Compared 
with these conventional approaches, nanosuspension tech-
nology may be an ultimate universal applicable technology 
to process these poor water-soluble drugs. The increase in 
dissolution velocity, saturation solubility, and bioavailability 
are the general advantages of nanosuspension formulations 
compared with microparticulate delivery systems, especially 
below 1–2 µm.12 As the nanosuspension was stabilized by a 
minimum of surfactants, and the drugs remained in a solid 
state, the formulation has low toxicity, higher mass per vol-
ume loading, and higher physiochemical stability.16
Compared with the previous publications in our lab and 
some other groups,11,12,17 the specialness of this present study 
is obvious. In previous publications, we mainly focused on the 
systematically investigated and constructed   nanosuspension 
drug-delivery systems such as   physicochemical properties 
and morphology analysis. Therefore, most of these works 
were carried out within colloidal and nanotechnology 
fields, and little research was performed on cell lines and 
pharmacodynamics.
It is self-evident that the physical properties of the 
drug’s vehicle could influence drug efficacy.18 In our previ-
ous studies, we developed and constructed ORI nanosus-
pension with acceptable ingredients, and we were able to 
formulate ORI nanosuspension that could be re-dispersed 
and diluted with water to any needed dilution without 
phase separation and without drug aggregation.11,19–22 It has 
been documented that the drug efficacy can be enhanced 
or degraded through nanoparticle,23,24 micelles,25 and 
liposomal formulations.26 Nevertheless, relatively few 
studies have been carried out concerning the influence of 
the nanosuspension of a drug on its antitumor efficacy.22,27 
Thus, in the present study, we demonstrated that nanosus-
pension could influence the ORI efficacy on proliferation 
and apoptosis of PC-3 cells.
Materials and methods
compound and materials
ORI (99% pure) was obtained from Shanxi Huike Plants 
Exploitation (Xian, China). ORI solution was prepared as our 
previous method described.11 Stock solutions of ORI were 
prepared by dissolving in dimethyl sulfoxide (DMSO) and 
the aliquots stored at −20°C prior to use. MTT [3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and DMSO 
were purchased from Sigma Chemical (St. Louis, MO). Fetal 
bovine serum (FBS) was supplied by FMG Biotech Co., Ltd 
(Shanghai, China). Trypsin was obtained from GIBCO BRL 
(Gaithersburg, MD). Propidium iodide (PI), RNase A and 
annexin V-FITC were purchased from KeyGen   Biotechnology 
(  Nanjing, China). All the other chemicals and solvents were of 
chromatographic and pharmaceutical grade and used without 
additional treatments.
Pc-3 cell culture
The human prostatic carcinoma PC-3 cells were grown in RPMI 
1640 medium (GIBCO, Billings, MT) supplemented with 10% 
FBS and 1% antibiotic solution (penicillin 100 U/mL and 
streptomycin 100 µg/mL). Cells were maintained at 37°C in a 
humidified atmosphere of 5% CO2. The medium was changed 
every second day, and cells were subcultured when confluency 
reached 90% by 0.25% trypsin at 37°C.
Preparation of OrI nanosuspension
To produce the ORI nanosuspension, HPH technology 
was applied. Briefly, ORI coarse powder (1%, w/v) was 
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dispersed in an aqueous surfactant solution containing 0.5% 
(w/v) lecithin, 0.1% (w/v) hydroxy-propyl methyl cellulose 
(HPMC), and 0.1% (w/v) polyvinylpyrrolidone (PVP) 
under magnetic stirring. The obtained mixture was firstly 
disintegrated into microparticles by high shear homogenizer 
using Ultra-Turrax® T25 (IKA, Germany) at 15,000 rpm for 
5 minutes. The nanosuspension was then prepared using a 
piston-gap high pressure homogenizer EmulsiFlex-C3 (Aves-
tin Inc., Ottawa, Canada) equipped with a heat exchanger. 
At first, 5 cycles at 500 bar and 10 cycles at 1000 bar were 
conducted as pre-milling step, and then 20 cycles at 1500 
bar were run to obtain the nanosuspension.
For long-term stability, mannitlo was used as cryopro-
tectant for freezing the nanosuspension for 48 hours, and 
then freeze-dried with lyophilizer (FD5, SIM, USA). The 
ORI nanosuspensions were rapidly cooled down to −80°C 
for 48 hours (DW-HL218; Shanghai Huayan Co., Ltd, China), 
and then freeze-dried for 48 hours at −55°C and at a pressure 
of 15 mTorr. The mean particle size of the obtained nano-
suspension was 912.5 ± 17.6 nm, as measured by Zetasizer 
(3000 SH; Malvern Instruments Ltd., UK).
estimation of cell viability
The effect of ORI solution and ORI nanosuspension on cell 
viability was assessed by a colorimetric MTT assay. Briefly, 
PC-3 cells (1 × 106 cells) were seeded in 96-well culture 
plates and allowed to adhere overnight at 37°C in a humidi-
fied, 5% CO2 atmosphere. PC-3 cells were incubated with 
ORI nanosuspension and free ORI at the concentrations of 
9.375, 18.75, 37.5, and 75 µmol/L for indicated time periods, 
respectively. The control group received drug-free medium 
with 0.05% v/v DMSO. Subsequently, MTT (5 mg/mL) was 
added to each well. After incubation at 37°C for 4 hours, the 
medium was discarded and 150 µL DMSO was added into 
each well. The optical density was measured by a microplate 
reader at a reference wavelength of 630 nm and a test wave-
length of 570 nm. The cytotoxicity of the ORI nanosuspension 
was expressed as IC50 (concentration of 50% inhibition rate 
relative to controls, which was estimated from linear regres-
sion analysis of experimental data). The percentage of cell 
growth inhibition was calculated as follows: cell inhibitory 
ratio (%) = (A570control − A570sample)/A570control × 100%.
Fluorescent morphological assay
PC-3 cells were seeded into 6-well culture plates at a density 
of 1 × 105 cells per well and incubated with free ORI and 
ORI nanosuspension at a concentration of 25 µmol/L for 
24 hours. Free ORI was prepared by dissolving ORI in 0.1% 
v/v DMSO. The control group received drug-free medium 
with 0.1% v/v DMSO. After cells were washed with PBS 
3 times and collected, the cells obtained were stained with PI 
for 5 minutes at room temperature and then observed under 
reverse fluorescence microscopy (Nikon, Japan).
Flow cytometric analysis of cell  
cycle distribution
The analysis of cell cycle distribution was measured by 
staining DNA with PI as described by the manufacture’s 
protocol. Treated or untreated PC-3 cells were harvested and 
washed into conical tubes, fixed in cool 70% ethanol at 4°C 
overnight, and then incubated with 0.5 mL PI/Triton X-100 
staining solution with ribonuclease A for 30 minutes at room 
temperature. For each cell population, at least 10,000 cells 
were analyzed by FACS. The distribution of different DNA 
contents was analyzed by FACScan flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ).
evaluation of apoptosis
The transversion of phosphatidyl serine from the inner 
to outer plasma membrane leaflet, an initial event in the 
apoptotic pathway, was assessed by dual dye staining using 
annexin V-FITC/PI.3,28 PC-3 cells were exposed to different 
concentrations of free ORI and ORI nanosuspension for 
24 hours and allowed to adhere. The control group received 
drug-free medium with 0.05% v/v DMSO. At the end of the 
treatment period, the control (untreated) and treated cells 
were harvested and washed with cold PBS at 1200 rpm 
for 5 minutes. Then 1 × 105 cells were collected and gently 
resuspended in 500 µL binding buffer. 5 µL annexin V-FITC 
and 5 µL PI were added and incubated with cells in the dark 
for 10 minutes. At the end of incubation, analysis by FAC-
Scan flow cytometer (Becton Dickinson) was carried out to 
discriminate between live and apoptotic cells.
statistical analysis
Results were expressed as means ± SD of replicate analyses. 
Data analyses were performed (where appropriate) using 
ANOVA for a single factor, factorial treatment model. 
Differences with P-values less than 0.05 (P , 0.05) were 
considered statistically significant.
Results and discussion
effects of OrI nanosuspension on growth 
inhibition of Pc-3 cells
Cells were cultured with ORI nanosuspension and free ORI 
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for 12, 24, and 36 hours, respectively. The results showed 
that both ORI nanosuspension and solution can significantly 
inhibit PC-3 cell growth. Meanwhile, ORI nanosuspension and 
solution inhibited PC-3 cell growth in a concentration- and 
time-dependent manner (Figure 2). A significant increase in 
inhibition rates was shown in ORI nanosuspension-treated 
cells, when compared with ORI solution-treated cells under 
the same experimental conditions. Also, ORI nanosuspension 
induced a stronger growth inhibition in PC-3 cells after longer 
incubation. As we can see in Table 1, the IC50 value of ORI 
nanosuspension was apparently lower than that of free ORI 
after the same incubation time, accounting for 42.33 µmol/L 
to 58.71 µmol/L, 22.59 µmol/L to 37.83 µmol/L, and 
17.53 µmol/L to 25.25 µmol/L after 12, 24, and 36 hours of 
treatment, respectively. These data suggest that ORI nanosus-
pension was much more effective at inhibiting the growth of 
PC-3 cells as compared with free ORI. Our MTT assay dem-
onstrated that ORI nanosuspension had a remarkable inhibitory 
effect on the proliferation of PC-3 cells. The inhibitory effect 
was increased with concentration and incubation time.
Previous reports demonstrate that ORI inhibited cell prolif-
eration and induced apoptosis in cancer cells.29,30 In the present 
study, we demonstrated that ORI nanosuspension could inhibit 
the growth of PC-3 cells, which were more significant than the 
ORI solution. It is possible that, like some other nanoparticle 
drug-delivery systems, the small size of the nanosuspension 
facilitated its adhesion to the cells and increased the contact 
area and time between the drug and cells.31,32
OrI nanosuspension induced 
morphologic changes in Pc-3 cells
To investigate whether ORI inhibits the growth of PC-3 cells 
through inducing apoptosis in PC-3 cells, we examined the 
apoptotic morphological changes with ORI. After treatment 
with free ORI and ORI nanosuspension at the concentration 
of 25 µmol/L for 24 hours, PI assay was conducted. Obser-
vation under reverse fluorescence microscopy showed that 
PC-3 cells treated with ORI presented marked morphological 
changes. In Figure 3, the most obvious suggestion is that 
there are more dyed cells in the ORI   nanosuspension than 
there are cells treated with free ORI and the controls. Typical 
morphologic changes of apoptosis including cell shrinkage, 
cell fragmentation, and cell irregularity in morphology were 
observed.33 The control cells showed normal morphology 
and only a thimbleful of cells were dyed. Meanwhile, as 
shown in Figure 3, the treatment of PC-3 cells with ORI 
nanosuspension resulted in more obvious changes in cell 
morphology in contrast to free ORI at the same dose. Results 
of PI staining demonstrated that ORI can induce apoptosis 
of PC-3 cells.34,35
Apoptosis is a form of self-regulated cell death, which 
differs from necrosis.36 Observation of morphological 
changes of ORI-treated cells suggested that ORI-induced 
PC-3 cell growth inhibition was involved in a mechanism 
of apoptosis.
OrI nanosuspension induced  
cycle arrest in Pc-3 cells
To confirm the effects of ORI on proliferation of PC-3 cell is 
mediated through inhibition of cell cycle progression, the cell 
cycle phases were analyzed by flow cytometry. Changes of 
cell cycle caused by ORI in PC-3 cells are shown in Figure 4. 
After treatment with free ORI for 24 hours, the percentage 
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Figure 2 MTT assay showing that the treatment of OrI nanosuspension and free 
OrI solution inhibit growth of Pc-3 cells in a time- and dose-dependent manner. 
results are expressed as mean ± standard deviation (n = 6). 
Notes: *P , 0.05, **P , 0.01, ***P , 0.005 versus the same dose of free OrI 
solution group.
Table 1 The Ic50 values (µmol/L) of oridonin (OrI) nanosu-
spension and OrI solution on Pc-3 cells (n = 6)
Formulation 12 hours 24 hours 36 hours
OrI 
nanosuspension
42.33 ± 3.21 22.59 ± 1.08 17.53 ± 1.53
OrI solution 58.71 ± 4.37 37.83 ± 4.64 25.25 ± 0.79International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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of S phase cells markedly decreased while the percentage 
of cells within the G2/M phase (10.6%–16.7%) markedly 
increased compared with that of the control cells. Further 
increases of ORI concentration had additional effects on the 
distribution of PC-3 cells in the cell cycle. As is shown in 
Figure 4, ORI nanosuspension could induce higher cell cycle 
arrest in contrast to the free ORI at the same concentration. 
Results indicated that ORI could arrest PC-3 cells in G2/M 
phase, and ORI nanosuspension induces a higher arrest 
compared with free ORI. Additionally, this arrest presents a 
concentration-dependent manner.2
Judging from the result obtained by MTT experiments, 
24 hours of ORI incubated with PC-3 was enough. In the 
12-hour groups of the MTT experiments, the superiority of 
the nanosuspension formulation was not entirely displayed. 
Nevertheless, 36-hour cell incubation was not necessary as no 
Control ORI solution (25 µM) ORI nanosuspensions (25 µM)
Figure 3 The effect of oridonin nanosuspension on apoptosis morphological change of Pc-3 cells (X200).
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new statistical difference appeared. Therefore, the incubation 
time of 24 hours was selected. Studies have shown that in 
addition to apoptosis, the growth inhibition induced by ORI 
treatment could partly be due to cell cycle arrest.37 Consistent 
with these results, our data showed the induction of growth 
inhibition of PC-3 cells by ORI could be of a significance of 
cell cycle arrest mechanism (together with a significance of 
apoptosis induction mechanism). Furthermore, we provided 
experimental evidence that the antitumor effect of ORI 
nanosuspension was associated with cell cycle arrest and 
morphological changes.37
Assessment of OrI nanosuspension-
induced apoptosis in Pc-3 cells
One of the early physiological changes in a cell undergoing 
apoptosis is the redistribution of the phosphatidylserine (PS) 
from the inner to the outer leaflet of the plasma membrane.38 
The binding of PS to annexin V conjugated to flourescein 
isothiocyanate (annexin V-FITC) was used to confirm apop-
tosis as described elsewhere.3,39
Annexin V-FITC/PI double-staining results showed that 
after treatment with ORI at different concentrations for 
24 hours, the early apoptosis rate of PC-3 cells increased 
with ORI concentration, reaching 0.0%, 7.9%, 10.0%, at 
concentrations of 0 µmol/L, 25 µmol/L, and 50 µmol/L, 
respectively. That is to say, ORI treatment induces apopto-
sis in PC-3 cells in a concentration-dependent manner. To 
further investigate the effect of nanosuspension in inducing 
apoptosis in PC-3 cells, PC-3 cells were treated with ORI 
nanosuspension at the same concentration and experimental 
conditions. It was found that ORI nanosuspension-treated 
PC-3 cells revealed the expected increase in the early apop-
tosis rate, reaching 0.0%, 12.0%, 16.8%, at concentrations of 
0 µmol/L, 25 µmol/L, and 50 µmol/L, respectively. As shown 
in Figure 5 and Figure 6, ORI nanosuspension presented a 
higher early apoptosis rate when compared with free ORI. 
Results showed that ORI could induce early apoptosis in 
PC-3 cells in a concentration-dependent manner, and there 
was a more prominent apoptosis rate in ORI nanosuspension-
treated cells.
Most of the present anticancer drugs mediate their effect 
via apoptosis induction in cancer cells, and apoptosis is 
suggested as one of the major mechanisms for the targeted 
therapy of various cancers including prostate cancer.40 
We demonstrated that ORI could inhibit the growth of 
MCF-7 cells by apoptosis induction and arresting cell-cycle 
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progression. Moreover, ORI nanosuspension was more 
significant than ORI solution.
Conclusion
In the present study, our data indicate an increased apoptosis 
in the ORI nanosuspension treatment group as compared 
with the solution group or the untreated control. In sum-
mary, ORI nanosuspension suppressed the PC-3 prolifera-
tion and enhanced the apoptosis of human prostate cancer 
PC-3 cells. These data suggest that nanosuspension may 
be an optimized ORI delivery formulation for prostate 
cancer therapy.
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